Alpine Global Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Alpine Global Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-150,000	Closed	-$102K	–	427
2020 Q4	$102K	Sell	150,000 -602,739	-80%	-$1.28M	0.02%	156
2020 Q3	$1.69M	Buy	752,739 +229,811	+44%	+$656K	0.35%	43
2020 Q2	$1.87M	Buy	522,928 +97,928	+23%	+$353K	0.33%	55
2020 Q1	$1.61M	Buy	425,000 +250,550	+144%	+$825K	0.34%	42
2019 Q4	$528K	Buy	+174,450	New	+$454K	0.11%	131

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Alpine Global Management's BMY.RT Position: Q1 2021 in Review

Alpine Global Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 150,000 shares — an estimated $102K sold.

Alpine Global Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.87M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Alpine Global Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Alpine Global Management sold 150,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $102K.
Alpine Global Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Alpine Global Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.87M in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Alpine Global Management's 13F filing for Q1 2021, filed 13 May 2021.